secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tempest Therapeutics, Inc. (TPST)
CIK:        0001544227
Form:       8-K
Filed at:   2021-08-12T23:59:59+00:00
Accession:  0001193125-21-244725
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tempest Therapeutics Q2 net loss $7.1M; cash $68.5M; appoints Ronit Simantov to board
--------------------------------------------------------------------------------

- Closed merger and $30M PIPE in June 2021; cash position $68.5M vs $18.8M at Dec 2020; runway extends into Q1’23.
- Net loss $7.1M ($7.63 per share) vs $5.2M ($11.42) in Q2 2020; six-month net loss $12.4M ($17.30).
- TPST-1120 selected 600mg BID RP2D; observed deep confirmed partial response in combination with nivolumab in RCC.
- Appointed Ronit Simantov, M.D. as Class III director effective Aug 6, 2021; granted option for 6,635 shares.
- TREX-1 inhibitor advanced to picomolar IC50 potency; in vivo efficacy shown in mouse tumor model.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1544227/000119312521244725/0001193125-21-244725-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1544227/000119312521244725/d186207d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-244725

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer